Catherine Ann Shu, MD

Articles

NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations

November 25th 2021

Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.

Other Agents Targeting EGFR Exon 20 Insertion Mutations in NSCLC

November 18th 2021

Experts briefly review a number of other agents in NSCLC that target EGFR exon 20 insertion mutations.

Key Differences Between Amivantamab and Mobocertinib in NSCLC

November 18th 2021

Shared insight on the differences between amivantamab and mobocertinib and when they may be appropriately used in patients with NSCLC.

NSCLC: Mobocertinib for Patients With EGFR Exon 20 Insertion Mutations

November 11th 2021

Considerations for the FDA approval and practical use of mobocertinib in patients with EGFR exon 20 insertion mutations in NSCLC.

NSCLC: Amivantamab for Patients With EGFR Exon 20 Insertion Mutations

November 11th 2021

Considerations for the FDA approval and practical use of amivantamab in patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.

NSCLC: Standard Treatment Approaches for EGFR Exon 20 Insertion Mutations

November 4th 2021

Current standard-of-care approaches toward the management of patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

EGFR Exon 20 Insertion Mutations as a Therapeutic Target in NSCLC

November 4th 2021

In the setting of non–small cell lung cancer, experts consider the importance of EGFR exon 20 insertion mutations as a therapeutic target.

NSCLC: Overcoming Barriers to Testing and Molecular Profiling

October 28th 2021

Erminia Massarelli, MD, MS, PhD, shares insight on potential barriers to appropriate molecular testing in patients with non–small cell lung cancer.

The Evolving Landscape of Molecular Testing for NSCLC

October 28th 2021

Experts take a broad look at how molecular profiling has impacted the treatment landscape of non–small cell lung cancer.

Dr. Shu on the MOA of Amivantamab in EGFR Exon 20 Insertion–Mutated NSCLC

February 19th 2021

Catherine Ann Shu, MD, discusses the mechanism of action of amivantamab in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer.